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A B S T R A C T
Lung cancer is the main cause of cancer death worldwide. Non-Small Cell Lung Carcinoma (NSCLC) is the most
common subtype of lung cancer, and the prognosis of NSCLC patients in advanced stages is still very poor. Given
the need for new therapies, the metabolism of NSCLC has been widely studied in the past two decades to identify
vulnerabilities that could be translated into novel anti-metabolic therapeutic approaches. A number of studies
have highlighted the role of glucose and mitochondrial metabolism in the development of NSCLC. The metabolic
properties of lung tumors have been characterized in detail in vivo, and they include high glucose and lactate use
and high heterogeneity regarding the use of nutrients and mitochondrial pathways. This heterogeneity has also
been observed in patients infused with labeled nutrients. We will summarize here the knowledge about the use of
amino acids, fatty acids and carbohydrates in NSCLC that could lead to new combination treatments.
1. Characteristic features of NSCLC and association with
metabolic parameters
Lung cancer is the main cause of cancer death worldwide in both
sexes [1]. Non-small cell lung cancer (NSCLC) accounts for about 85%
of lung cancer and is classified into three major histological subtypes:
lung adenocarcinoma (LUAD), lung squamous cell carcinoma (LUSC)
and large cell carcinoma. During the last decade, a significant im-
provement in the clinical outcome was achieved, mainly due to the
incorporation of targeted therapies in genetically selected subpopula-
tions of patients and the impressive achievements of immunotherapy in
advanced and locally advanced NSCLC [2]. However, only a minority of
NSCLC patients will achieve long-term survival [3] and therefore,
deeper knowledge about lung cancer biology is needed to unravel ef-
fective therapeutic strategies.
Deregulation of cellular energy metabolism to support continuous
cell growth and proliferation is a hallmark of cancer [4]. In spite of
significant advances on the understanding of vulnerabilities of cancer
cells in vitro, the complexity of the tumor microenvironment has hin-
dered the discovery of effective metabolic inhibitors.
Glucose is an essential nutrient required for multiple metabolic
pathways in proliferating cells (Fig. 1). It is possible that a high supply
of glucose benefits tumors. In fact, high blood glucose and a clinical
diagnosis of diabetes have been associated with a higher incidence and
mortality in many types of cancer, including NSCLC [5]. In particular,
epidemiological studies suggested that pre-existing diabetes was asso-
ciated with lung cancer mortality [6]. A role for diabetes in the prog-
nosis of NSCLC patients is now becoming established. Some retro-
spective studies showed that diabetes as well as high levels of fasting
plasma glucose were associated with worse outcome of NSCLC patients
treated with surgical resection or concurrent chemoradiotherapy [7],
while this association was not observed in small cell lung cancer (SCLC)
patients [8]. The reason, however, why diabetes is associated with poor
prognosis is unclear. Diabetes could be linked to NSCLC through a di-
rect effect of hyperglycemia on the tumor that would promote meta-
bolic advantages to glucose-avid cells. However, its effects could also be
indirect, due to the effects of hyperinsulinemia on the tumor, in-
flammation associated with diabetes or shared risk factors like obesity.
According to Warburg’s hypothesis, hyperglycemia could accelerate
the proliferation of cancer cells, as they can obtain essential metabolites
and energy mainly from glucose fermentation, even in aerobic condi-
tions [9]. Data from patients and mouse models indicate that lung tu-
mors are indeed dependent on glucose metabolism, and increased ex-
pression of the glucose transporter GLUT1 or glycolytic enzymes
correlate with poor prognosis in advanced [10–12] and early stage lung
cancer patients [13]. GLUT1 overexpression was independently asso-
ciated with worse overall survival in patients with surgically resected
squamous NSCLC. In vitro, it has been described that glucose levels
determine sensitivity to radio- and chemotherapy in multiple cell types:
cells growing in low glucose show more sensitivity. This suggests that
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hyperglycemia may be related to poor prognosis after treatment be-
cause it would reduce cell death induced by the therapy [14]. Hy-
perglycemia was also associated with a reduced antiproliferative effect
of chemotherapy in preclinical models [15], although these results have
not been confirmed yet in clinical trials.
While the association of high glucose with poor prognosis is clear,
whether glucose is mostly used anaerobically through glycolysis in
NSCLC is not. In this review, we will revise the metabolic properties of
NSCLC that could explain clinical associations with metabolic para-
meters and that may help to unravel novel therapeutic opportunities.
2. NSCLC is driven by mutations that promote metabolic rewiring
Some advanced NSCLC tumors have been shown to be driven by the
oncogenic activation of tyrosine kinases. Mutations in the epidermal
growth factor receptor (EGFR) or v-Raf murine sarcoma viral oncogene
homolog B (B-RAF) and chromosomal rearrangements of the anaplastic
lymphoma kinase (ALK) gene and ROS1 are targetable, and this has
improved the treatment of patients in advanced stages [16]. There is
increasing knowledge indicating that these kinases also produce me-
tabolic changes in the tumor cells. The specific mechanisms by which
EGFR rewires NSCLC metabolism are widely studied, and it is known
that oncogenic EGFR signaling is involved in the regulation of glucose
metabolism [17], which will be described in more detail below.
KRAS mutations occur in around 30% of NSCLC, mainly in the non-
squamous subtype LUAD, and it is one of the most common driver
mutations causing constitutive activation of the gene and its down-
stream signaling [18]. Many efforts have been done to target KRAS,
from early discoveries on miRNA-based therapies [19] to more
advanced therapeutic strategies such as the G12C inhibitor AMG510
under development (NCT03600883). However, to date, clinicians do
not usually consider KRAS mutations in the clinical management since
they are not actionable [16]. KRAS is one of the most widely studied
oncogenes in terms of the metabolic changes that it produces, and the
growing evidence of KRAS-dependent metabolic features will be likely
translated into novel therapeutic avenues for NSCLC, as extensively
reviewed by Kerr and Martins [20]. Another non-actionable gene mu-
tation in NSCLC is LKB1, which is inactivated by mutation or deletion in
almost 20% of NSCLC. LKB1 is widely studied as the kinase that acti-
vates AMPK to rewire metabolism in response to starvation, and its
absence promotes sensitivity to drugs that target glucose or mi-
tochondrial metabolism [21].
3. Oncogenic mutations drive glucose uptake and its use in the
TCA
KRAS can drive glucose uptake and its mitochondrial oxidation. In
particular, Kerr et al. [22] had described that glycolysis is acquired as a
function dependent on the number of copies of mutant KRAS. They
demonstrated (i) an increase in glucose utilization, expression of GLUT
transporters and glycolytic enzymes coupled to increased channeling of
glucose-derived metabolites into the TCA cycle, and (ii) a glucose-de-
pendent management of reactive oxygen species (ROS) metabolism in
mutant KRASG12D/G12D NSCLC cells and murine tumors, but not in the
early stage-KrasG12D/WT heterozygous ones [22].
It was recently shown in KRAS-mut/p53−/− NSCLC mice models
that the genetic loss of AMPK, a kinase activated by low glucose or low
ATP, reduced tumor growth [23]. This was accompanied with a
Fig. 1. Metabolism of NSCLC.
Abbreviations: ACS, Acyl-CoA synthetase. GCS, glycine cleavage system. GLS1, glutaminase 1. LDH, lactate dehydrogenase. PC, pyruvate carboxylase. PDH, pyruvate
dehydrogenase. SHMT2, serine hydroxymethyltransferase 2. SSP, serine synthesis pathway.
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reduction in GLUT1 expression. In LKB1-deficient KRAS-mut/p53−/−
lung tumor cells, the remaining levels of AMPK activity were sufficient
to support survival [23]. These data helped to clarify the role of AMPK
in lung cancer. Besides a role of this kinase in sensing low glucose and
facilitating its uptake through GLUT1 transporter, AMPK activation
induced the expression of core lysosomal genes, helping cells cope with
nutrient stress [23]. The authors defined a core set of the 16 most
AMPK-dependent lysosomal genes in lung cancer cells and applied this
AMPK-dependent lysosomal gene signature to several public databases
of lung cancer patients. Interestingly, elevated lysosomal gene expres-
sion correlated with accelerated disease recurrence [23].
Other common mutations in NSCLC, such as those in EGFR gene,
have been shown to regulate not total GLUT1 expression but its loca-
lization to the plasma membrane in a PI3K/AKT-dependent manner
[17]. Alternatively, glucose can enter into the cell through other than
GLUT-dependent mechanisms, as shown for SGLT1 in EGFR mutant
lung cancers [24] or SGLT2 in premalignant and early well differ-
entiated KRAS LUADs. This increased glucose transport may be an early
requirement to sustain the increased proliferation associated with
progression from premalignant to invasive NSCLC [25]. Importantly,
these distinct metabolic phenotypes during KRAS-dependent NSCLC
progression have different prognosis and therefore, they offer different
therapeutic susceptibilities.
Hexokinase 2 (HK2) catalyzes the phosphorylation of glucose to
glucose-6-P creating a concentration gradient that facilitates glucose
entry into the cancer cells (Fig. 1). Expression and activity of this en-
zyme was induced by KRAS-mutation [26] and EML4-ALK rearrange-
ment [27] in NSCLC models. In particular, inhibition of HK2 impaired
KRAS-mut lung cancer development in murine models and reduced
lung cancer cell growth in vitro and in vivo by inhibiting nucleotide
synthesis and the TCA cycle [26]. EML4-ALK rearrangement, another
frequent oncogenic rearrangement in NSCLC, induced hypoxia-in-
dependent but glucose-dependent HIF1-α expression to drive HK2 ex-
pression and enhance glucose metabolism [27].
Several inhibitors of glucose transport and drugs targeting enzymes
of the early phases of glycolysis like HK2 have been tested for decades
against a variety of tumors (Fig. 2) [14]. In cells in culture and in mouse
cancer models, 2-deoxyglucose and other inhibitors of glycolysis have
shown effectiveness against LUAC and LUSC [28]. However, these in-
hibitors are still not used in the clinic, as results from clinical trials have
been disappointing. It is possible that this is due to cells adapting their
metabolism rather than undergoing cell death, or that the therapeutic
window is small because other organs, including the immune system,
require glucose. However, multiple studies indicate that glucose re-
duction confers sensitivity to chemotherapy, radiotherapy and targeted
therapies. This, combined with the clinical data on GLUT1 as a prog-
nosis marker suggests that it is worth testing combinations of therapies
that include GLUT1 and hexokinase 2 inhibitors.
4. Mitochondrial metabolism in lung cancer patients and animal
models: glucose as fuel
Glucose can be metabolized via glycolysis to pyruvate and, in the
presence of oxygen, pyruvate is metabolized to CO2 in the mitochondria
through the Krebs/tricarboxylic acid (TCA) cycle and OXPHOS to
generate large amounts of ATP [29]. In the absence of oxygen, pyruvate
can be metabolized to lactate (anaerobic glycolysis), a biochemical
reaction far less efficient than the TCA cycle and OXPHOS in generating
ATP. However, rapidly proliferating cells (including cancer cells) can
metabolize glucose to lactate in spite of the presence of oxygen, a
process widely known as Warburg effect (or aerobic glycolysis), to
quickly obtain energy and glucose-derived metabolites for macro-
molecular synthesis [29].
NSCLC, like many other cancer types, requires a high intake of
glucose, and positron emission tomography (PET) imaging based on
glucose-based tracer (F-FDG) became a standard diagnostic tool to
assess tumor extension. However, whether glucose is utilized anaero-
bically to generate lactate in a classical “Warburg” manner, is still
unclear in this type of cancer. The fate of glucose may depend on the
mutational signature and even the intratumor location and perfusion of
cells.
Metabolic flux analyses showed that KRASG12D NSCLC cells cultured
in vitro produce lactate from glucose [30]. While these cells still used
the mitochondria, the majority of the TCA cycle intermediates came
from glutamine metabolism. In contrast, in vivo metabolic flux analyses
of lung cancer models demonstrated that concomitantly to the pro-
duction of lactate (which was higher than in normal lungs due to higher
glucose uptake in tumors), it’s primarily glucose rather than glutamine
that accounts for the fluxed carbon source into the TCA cycle [30]. By
labeling glucose or pyruvate, Davidson et al. confirmed that glucose-
derived metabolites enter the TCA cycle either through Pyruvate De-
hydrogenase (PDH) or Pyruvate Carboxylase (PC) (Fig.1), which are
required for glucose oxidation into the TCA cycle by converting pyr-
uvate into acetyl-CoA and oxaloacetate, respectively [30]. In support of
that, tumor development was impaired in genetically engineered lung
cancer models by blocking the mitochondrial metabolism through the
inhibition of PDH and PC. NSCLC cell lines, however, did not show
reduced proliferation when these enzymes where knocked-out in vitro,
underscoring the relevance of environmental impact on glucose utili-
zation [30]. Altogether, these data suggest that tissue environment
determines the fate of glucose in KRAS-driven lung cancer and point out
that mitochondrial oxidative metabolism of glucose occurs in vivo and is
necessary for tumor formation.
Recently, in a landmark study, Hensley et al. analyzed the fate of
glucose in patients infused with radioactive glucose and found that
NSCLC patients present inter- and intra-tumoral heterogeneity in terms
of glucose oxidation, although they could not find associations between
higher/lower glucose metabolism and specific mutations [31]. Overall,
high glucose uptake by FDG-PET imaging was found in all tumors, and
authors found higher production of lactate and TCA intermediates in
tumors than in the normal lungs. They demonstrated that part of the
produced acetyl-CoA could enter into the TCA cycle mainly via PDH and
PC (at lesser extent), but acetyl-CoA could also be derived from lactate
as demonstrated in mouse tumors [31]. In particular, by using DCE-MRI
as a differential contrast technique, they found intra-tumor hetero-
geneity in terms of tumor perfusion. Then, they performed metabolite
extraction and enrichment analysis to determine glucose metabolism in
different areas. Low-perfused regions of the tumor presented higher
rates of glycolysis coupled with increased mitochondrial metabolism of
glucose through the TCA cycle and oxidative phosphorylation (OX-
PHOS), while well-perfused regions behave more like non-tumoral
lungs and do not show such glucose oxidative metabolism. Well-per-
fused regions present lower PDH activity and lower citrate and gluta-
mate production from glucose than the low-perfused regions [31]. In
addition, RNA-seq data from these differentially perfused regions sug-
gested that other nutrients could be fueling the TCA cycle of well-per-
fused areas, as genes related to lysosomes and amino acid metabolism
appeared to be significantly deregulated [31]. Therefore, they postu-
lated other possible fuels such as fatty acids, amino acids or lactate as
alternative oxidized nutrients in well-perfused tumoral areas [31]. The
authors suggested that since glucose is more efficient than other nu-
trients in terms of energy produced by oxygen consumed, and since
glucose usually diffuses better in low-perfused regions, it might be the
nutrient preferentially used in low-oxygen areas of these heterogenic
tumors.
5. Mitochondrial metabolism in lung cancer patients and animal
models: lactate as a carbon source
Lactate has been recently shown to be a more common nutrient in
tissues than previously thought [32]. Hui S. et al, measured the fluxes of
circulating metabolites in mice using intravenous infusions of 13C-
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labelled nutrients and found that circulating lactate had higher turn-
over flux (consumption vs. excretion) than glucose, acetate, alanine,
pyruvate, glycerol and glutamine [32]. They found that lactate is the
primary carbon source for the TCA cycle in all tissues except in the
brain. The authors also analyzed the contribution of glucose to the TCA
cycle in genetically engineered KRAS-lung tumor mice and found that it
occurs mostly indirectly, through circulating lactate, as infused 13C-
lactate extensively labels TCA cycle intermediates in these tumors [32].
They postulated that the high flux of lactate reflects a high fraction of
pyruvate being excreted as lactate from some cells undergoing anae-
robic glycolysis and a high fraction of tissue pyruvate being derived
from circulating lactate. The activity of Lactate Dehydrogenase (LDH)
A/B and lactate transporters monocarboxylate transporter-1/4 (MCT1/
4) was required for the shuttling of lactate between tissues (Fig. 1). This
shuttling may underlie the high flux of circulating lactate, which would
be metabolized in the mitochondria of a different location (cell, tumor
area, organ) [32]. In support of that, infusions of glucose and lactate in
NSCLC human patients and orthotopic mice models revealed con-
comitant metabolism of both nutrients, with extensive labeling of TCA
cycle metabolites from lactate, suggesting that glycolysis and the TCA
are uncoupled [33]. In addition, it was found that deletion of MCT1
from tumor cells eliminated lactate-dependent metabolite labeling in
vivo in NSCLC mice models [33]. In principle, the use of LDH to produce
lactate from glucose/pyruvate and its use to produce pyruvate from
circulating lactate seem contradictory. However, this still could be in
line with the findings that the contribution of glucose to the TCA cycle
is mostly through circulating lactate in lung cancer, with some cells
producing lactate from glucose and other cells using the lactate for the
TCA cycle [32] (Fig. 1). It should be noted that some controversy exists
as to whether these labeling experiments would accurately reveal net
contributions of each nutrient. Because lactate and pyruvate can be
interconverted by LDH, a phenomenon named “isotope exchange” may
occur, leading to overestimation of the net contribution of lactate to the
TCA [34].
Regardless of whether lactate transporters contribute mainly to lung
cancer by importing or exporting lactate, numerous data suggest that
they could be a good therapeutic target against NSCLC and other tu-
mors. AZD3965 was designed to selectively inhibit Monocarboxylate
transporter-1 (MCT1) which extrudes lactate, and it has entered phase I
clinical trials (Fig. 2). In a similar manner, LDH could contribute to
cancer by promoting lactate catabolism or by supporting anaerobic
glycolysis by generating lactate, a reaction favored by the LDH subunit
isoform LDH-A (Fig. 2). Genetic deletion of LDH-A has been shown to
induce tumor regression of established tumors and to impair tumor
development of KRAS- and EGFR-driven lung cancer models in an al-
lele-dependent manner [35]. In fact, this allele-dependent reduced
tumor growth was accompanied by a decrease in lactate production and
increased NADH and pyruvate accumulation [35]. This suggests that
fermentative glycolysis is a key bioenergetic pathway in lung cancer
development and progression. Importantly, the authors showed that
LDH-A attenuation led to reduced glycolytic flux in vitro, in vivo, and ex
vivo, and they only observed reactivation of the mitochondrial meta-
bolism (labeled citrate and aspartate from glucose) in vitro [35]. This
suggests that LDH-A inhibition could be useful for NSCLC patients and
Fig. 2. Metabolic targets in NSCLC.
Potential target enzymes are shown in blue, and inhibitors in red. Inhibitors that have been tested in preclinical or clinical settings are included.
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highlights the role of the tumor microenvironment in metabolic re-
programming.
It is worth mentioning that, in human NSCLC patients, elevated
mitochondrial oxidation of lactate at the time of diagnosis in stage I-II
patients was associated with higher rates of recurrence and metastasis
[33]. Furthermore, EGFR-mutant NSCLC tumors present lower lactate
consumption and more homogeneous patterns of lactate oxidation
within the tumor than the KRAS-mutant ones, which presented higher
intra-tumor heterogeneity for lactate oxidation [33]. In other situations,
lactate has been shown to serve as a gluconeogenic source for KRAS-
mut lung cancer cells grown with low glucose in vitro. These cells
generated glucose via gluconeogenesis through the mitochondrial en-
zyme PCK2 [36]. Also, in patient-derived xenografts (PDX) models of
NSCLC fed with a labeled glucose-liquid diet, gluconeogenesis was in-
creased in PDX tissues when compared with tumor slices infused ex
vivo, as evidenced by a higher enrichment of labeled glucose-6 P and
fructose-6P [37]. Together, glucose and lactate metabolism seem to be
coupled and uncoupled depending on the anatomical site and driver
mutation, following spatio-temporal dynamics regarding the intra-
tumor oxygen availability and potentially involving the contribution of
other organs (i.e. systemic metabolism) for cell growth and survival.
6. Glutamine metabolism
In some cancer cells, glutamine is used as a source of nitrogen for
amino acid and nucleic acid synthesis, and it can be essential to re-
plenish the TCA cycle. For this reason, several strategies to target glu-
tamine metabolism have been proposed, including the use of inhibitors
of glutamine uptake and catabolism and circulating glutamine-de-
pleting enzymes. Many reports point towards the essentiality of gluta-
mine for NSCLC lines in vitro [30,38,39]. Several oncogenes, including
KRAS, could drive glutamine metabolism in these cells. Specifically, it
was shown that glutamine metabolism is enhanced in KRAS-mut lung
cancer cells in vitro either through PI3K/AKT [38] or ATF4 [39] de-
pendent signaling.
However, the essential nature of glutamine for the replenishment of
the TCA cycle in NSCLC was not observed in vivo: glutamine flux ana-
lyses of KRAS-driven lung tumors in mice revealed only minimal la-
beling of glutamate and TCA intermediates [30]. Additionally, neither
genetic deletion nor pharmacological inhibition of the mitochondrial
enzyme glutaminase (GLS1) affected the growth of KRASG12D-induced
lung tumors [30]. Moreover, in early stage NSCLC, no differences in
GLS1 expression were found between human tumors and their normal
counterparts, while pyruvate carboxylase was way higher in tumors
than in nonmalignant lung samples [40]. This suggests that mi-
tochondrial input into the TCA cycle (anaplerosis) occur mainly
through glucose- instead of glutamine-derived metabolites. These re-
sults were supported by the low glutamine and high glucose utilization
observed in lung tumor sections freshly “infused” ex vivo with labeled
nutrients. In cancerous and non-cancerous tissues, GLS1 was found
active (as tissue slices produced labeled glutamate) but no enrichment
in labeled glutamine-derived metabolites was found in the TCA cycle
[40]. In this model, suppression of pyruvate carboxylase reduced cell
proliferation in vitro and in vivo, and this was accompanied by a de-
crease in anaplerotic input into the TCA cycle and reduced nucleotide
and lipid biosynthesis. This could not be compensated by the abundant
supply of glutamine [40]. One of the reasons that could explain the use
of glutamine by lung cancer cells in vitro is the presence of cystine,
which favors the use of glutamine by these cells for TCA anaplerosis
[41]. On the other hand, these studies and a subsequent thorough ex-
amination of pyruvate carboxylase dependency on cell lines suggest
that pyruvate carboxylase would be an interesting druggable target for
a subset of NSCLC [42].
Certain mutations caused more dependence on glutamine metabo-
lism than KRAS, such as those occurring in the KEAP1/NRF2 pathway,
which have been identified in 23% of LUAC [18] and 31% of LUSC
[43]. Loss of Keap1 caused the stabilization, nuclear localization and
hyperactivation of NRF2 (a master transcriptional regulator of the
oxidative stress response), and this was shown to accelerate KRAS-mut
lung cancer progression in vivo [44]. Authors defined two genetic sig-
natures related to “KEAP1 mutation” and to “NRF2 core target genes”,
and found that both were upregulated in stage IV lung tumors and as-
sociated with worse overall survival. Importantly, the authors showed
that Keap1-mutant cancer cells presented a high dependency on the
glutamine transporter SLC1A5, with increased glutamine consumption,
and have subsequent higher sensitivity to glutaminase inhibition than
KRAS-mut/p53−/− lung cancer cells in vitro and in vivo. Thus, the
presence of Keap1 or Nrf2 mutation may serve to therapeutically stra-
tify patients for pharmacological inhibition of glutaminase. This was
further supported by the fact that human patients with KRAS-mut lung
cancer harboring KEAP1 loss-of-function mutations or NRF2 gain-of-
function mutations respond better to glutaminase inhibition [44]. Also,
mutations in the EGFR gene (15%) [18] have been found to be involved
in reprogramming glutamine amino acid metabolism. Conversely to
what has been described for KRAS-mut lung cancer mice models in vivo
[30], glutamine metabolism is increased in EGFR-mut lung cancers and
inhibition of GLS in combination with the EGFR inhibitor erlotinib
acted synergistically in vitro and in vivo inducing tumor regression [45].
In fact, the authors proved that the dual treatment reduced glucose and
glutamine uptake and correlated with better response to treatment in
vivo, by inducing energetic stress (decreased glutathione and ATP
production) accompanied by an increased in the phosphorylated-AMPK
and reduced MYC levels in treated lung tumor xenografts, finally re-
sulting in cell death [45].
In summary, glutaminase inhibitors may prove effective for sub-
types of NSCLC but their effect may likely be dependent on the driver
mutations. The GLS1 inhibitor CB-839 is currently being tested in
clinical trials for advanced NSCLC in combination with immunotherapy
(NCT02771626) and will soon be tested in combination with the EGFR
inhibitor osimertinib (NCT03831932).
7. Metabolism and essential role of other amino acids
Serine, a non-essential amino acid, is the major carbon source for
one-carbon metabolism and it can be synthetized de novo from the
glycolytic intermediate 3-phosphoglycerate (3-PG) through the serine
synthesis pathway (SSP, Fig. 1) [46]. Serine is catabolized by the mi-
tochondrial enzyme SHMT2 to glycine, which is then catabolized by the
mitochondrial enzymatic complex GCS (glycine cleavage system; from
which glycine decarboxylase is the core enzymatic component) to yield
a one-carbon unit that is accepted by tetrahydrofolate (THF). Then, by
the action of the mitochondrial enzymes MTHFD1L/2/2 L, the modified
THF will donate its one-carbon unit for purine synthesis. Specifically in
NSCLC, it was shown that cells with high NRF2 activity displayed ele-
vated levels of serine consumption compared to cells with low NRF2
activity [47]. NRF2 regulated the serine/glycine metabolism by indu-
cing the expression of SHMT2 (among other serine/glycine metabolic
enzymes) via ATF4 to support glutathione and nucleotide production. In
addition, the authors showed that elevated expression of a gene sig-
nature that includes enzymes of the serine synthesis pathway and
SHMT2 was associated with poor prognosis in human NSCLC [47]. Si-
milarly, it was demonstrated that glycine decarboxylase expression
correlated with low survival in lung cancer patients and it drove cel-
lular transformation and NSCLC tumorigenesis through its metabolic
activity, specifically by modulating glucose metabolism and pyrimidine
synthesis [48]. In particular, glycine decarboxylase was found elevated
in lung tumor-initiating cells accompanied by high levels of the onco-
genic stem cell factor LIN28B, among other serine/glycine metabolic
enzymes [48]. Together, these results suggested that inhibition of the
serine/glycine mitochondrial metabolism may open new avenues for
lung cancer targeted therapies, specifically for the KRAS-Keap1/NRF2
oncotypes.
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Other amino acids have been recently described to be relevant for
the growth of KRAS-mut lung cancer. It was shown that KRAS-driven
NSCLC can incorporate free branched-chain amino acids (BCAAs), such
as leucine and valine, and use them as a nitrogen source for protein and
nucleotide biosynthesis [49]. Levels of the mitochondrial enzyme Bcat2
were found increased in lung tumors compared to normal lung and,
importantly, inhibition of BCAA catabolism blocked tumor growth in
vivo [49]. Although the authors showed that their metabolism did not
contribute to anaplerosis of the mitochondrial TCA cycle, they showed
that BCAA can be used for aspartate synthesis in the mitochondria. This
occurs via the transfer of nitrogen from the TCA cycle intermediate α-
ketoglutarate to form glutamate by Bcat2, which then is transferred to
oxaloacetate to form aspartate (see Fig.1), therefore contributing to the
nitrogen pool for nucleotide biosynthesis. Accordingly, levels of BCAA
in plasma where found to be lower in KRAS-mut lung cancer patients
compared to KRAS-mut pancreatic cancer patients [49], altogether in-
dicating that cancer metabolism is not only oncotype-dependent but
also environmentally driven (i.e. local nutrient availability, tissue of
origin and architecture, systemic metabolism, etc.).
Arginine auxotrophy, frequent in many tumors, has not been thor-
oughly described in NSCLC. However, a recent phase I clinical trial
suggested that patients with argininosuccinate synthetase 1
(ASS1)–negative tumors could benefit from arginine depletion therapy
through the use of ADI-PEG in combination with chemotherapy [50].
This finding should be confirmed in randomized trials and may not be
applicable to the majority of NSCLC patients, and actually arginine
depletion could potentially have the opposite effect. Arginine elimina-
tion from the microenvironment is a physiological immunosuppressive
mechanism: myeloid-derived suppressor cells (MDSC) produce and se-
crete arginase. Along these lines, a role for arginine depletion in lung
cancer was shown in a KRASG12D LUAD model, in which inhibition of
arginase 1/2 promoted anti-tumor immunity and tumor clearance.
Consistently, the concentration of arginine in the intracellular fluid of a
lung cancer (KP) model has been shown to be much lower than plasma
levels [51].
8. Mitochondrial lipid metabolism
Lipids are generated from glycolytic- and mitochondrial-derived
metabolites, they can be used to produce ATP and they are essential for
the synthesis of cellular membranes, vitamins, hormones, and other
metabolites for intracellular signaling [52]. Some tumors require fatty
acid synthesis, but NSCLC appears to be reliant on fatty acid catabolism.
Fatty acid oxidation is a mitochondrial pathway that provides ATP and
may offer therapeutic opportunities for KRAS-mut driven NSCLC. Acyl-
CoA synthetase (ACS) is a mitochondrial outer membrane enzyme that
catalyzes in the cytosol the first reaction before fatty acid oxidation
starts in the mitochondrial matrix. This enzyme is upregulated by KRAS
mutation and is highly expressed in human KRAS-mut NSCLC tissues
[53]. In particular, the isoform ACSL3 mediates survival and tumor-
igenesis of KRAS-mut lung cancer cells by promoting uptake, retention,
and β-oxidation of fatty acids [53]. Also, specific signaling lipids (i.e.
phosphatidylinositol and arachidonic-containing phospholipids) were
identified in KRAS-mut/high-MYC tumors but not in normal lungs; and
were associated to MYC signaling through the increased activity of
cPLA2 and COX-2 found in this model [54]. In addition, in vivo phar-
macological inhibition of COX/5-LOX pathways resulted in reduced
tumor burden of KRAS-mut/high-MYC tumors [54], suggesting that
catabolism of certain types of lipids could be involved in KRAS-mut
lung cancer progression and therefore serve as a potential target.
Strikingly, in a KRAS-mut lung cancer model, it has been recently
suggested that the tumor can rewire systemic metabolism, which con-
tributes to cancer progression [55]. Authors found that the tumor-se-
creted “waste” caused metabolic rewiring of the liver, including a pro-
inflammatory response and altered glucose and lipid metabolism.
9. Autophagy in NSCLC
Autophagy is a self-eating process that regulates normal cell
homeostasis in response to stress, but at the same time is required for
tumor maintenance since some metabolism by-products can potentially
serve as metabolic fuels for cancer cell proliferation and energy pro-
duction [56]. In this sense, extensive work has evidenced that autop-
hagy is increased in KRAS-lung tumors and that it acts to maintain
mitochondrial function and lipid catabolism [57], while its genetic
abrogation caused tumor regression to oncocytomas, a benign lesion
characterized by defective mitochondria and increased lipid storages
[57,58]. In addition, other functions have been attributed to KRAS-
dependent autophagy in lung cancer, such as the replenishment of the
TCA cycle for nucleotide synthesis and the regulation of the cellular
energy charge and redox homeostasis [59]. Autophagy inhibitors could
be useful in combination with other therapies. For instance, KRAS/p53
deficient mouse models of lung cancer have been shown to be depen-
dent on signaling by insulin receptor substrates 1/2 [60], and ablation
of these proteins or inhibition of Insulin Receptor/IGF Receptor sig-
naling led to a reduction of intracellular amino acids and sensitivity to
autophagy inhibition. This, therefore, points to a potential two-pronged
approach targeting these receptors and autophagy in KRAS-driven
NSCLC. The link between autophagy, metabolism and cancer, however,
goes beyond intracellular maintenance of nutrient pools. Autophagy is
required to maintain glucose homeostasis, since its whole-body deletion
impaired long-term survival of adult mice, which die of hypoglycemia
when fasted, and drove many other systemic metabolic alterations [58].
Whole-body autophagy is also beneficial for lung cancer, as systemic
deletion of autophagy also reduces tumorogenesis of an implanted
KRAS/p53 NSCLC cell line [61]. This has recently been attributed to an
unexpected effect of ATG7 deletion in the liver: the subsequent liver
damage promotes the release of arginase I, an arginine-degrading en-
zyme. The reduction of circulating arginine prevented the growth of
several tumors that are auxotroph for arginine, as is the case for the
lung cancer cell line employed in this study [61].
10. OXPHOS as a target: metformin and phenformin
Mitochondrial drugs used to treat diabetes have long been asso-
ciated with better prognosis of NSCLC. Metformin and phenformin ef-
fects have been attributed to inhibition of Complex I of the respiratory
chain. Their effects on lung cancer are likely pleiotropic and could in-
volve systemic effects as well as direct targeting of the tumor. In vitro,
numerous studies indicate that metformin is toxic to NSCLC cell lines,
although the doses used are much higher than those employed to treat
diabetic patients. On the other hand, metformin acts on the liver and
possibly on other organs to reduce systemic glucose levels by activating
AMPK. Several epidemiologic studies assessed the impact of anti-
diabetic therapy on cancer incidence and mortality and found an as-
sociation among metformin and decreased cancer mortality [62]. Based
on data from the Surveillance, Epidemiology and End Results registry
linked to Medicare claims, diabetic patients with advanced NSCLC who
were being treated with metformin at the time of lung cancer diagnosis
achieved longer overall survival than those who were not treated with
metformin [63]. In contrast, patients treated with insulin had higher
mortality rates [62]. Accordingly, diabetic patients with locally ad-
vanced NSCLC treated with concurrent chemoradiotherapy who were
receiving metformin had better clinical outcome than those being
treated with insulin [64]. These data are not in accordance with the
recent NRG-LU001 clinical trial, as the addition of metformin to con-
current chemoradiation did not improve clinical outcome in non-
diabetic patients with unresectable stage III NSCLC [65]. Given the
heterogenicity of NSCLC, we suggest that patients are selected based on
their tumor dependency on OXPHOS versus glycolysis, which can be
predicted, at least in Diffuse large B cell lymphoma, by the level of
GAPDH expression [66].
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Phenformin is another drug structurally similar to metformin that
was widely used as an anti-diabetic agent but has been more recently
discontinued due to unacceptable toxicity when used at effective doses
in humans. In the clinic, links with patient prognosis are therefore less
proven compared to metformin. Phenformin has been shown to be
highly effective against LKB1 deficient tumors in animal models, which
suggests that patient stratification according to driver mutations could
be highly relevant when testing metabolic therapies in patients [67].
Other drugs targeting different complexes of the respiratory chain
are being developed and tested in clinical trials against cancer. Among
these, IACS-010759 has shown efficacy in mouse models with muta-
tions in KRAS, p53 and the SWI/SNF chromatin remodeling complex
[68].
11. Concluding remarks
Anti-metabolite drugs have been used to treat NSCLC for decades;
amongst them, pemetrexed, an antifolate, is currently included in
standard chemotherapy regimes in combination with cisplatin or car-
boplatin for non-squamous NSCLC. In the last two decades, the in-
corporation of novel techniques such as metabolic flux analyses, and
the study of metabolic dependencies in murine models were crucial to
unveil the potential of new drugs targeting other metabolic pathways
beyond nucleotide synthesis, such as glycolysis, glutaminolysis or lac-
tate transport and LDH. One of the limitations of this type of studies is
that NSCLC is a highly heterogeneous disease, as has already been
shown in metabolic flux data obtained from patients. Also, as the
genomic context is highly relevant for tumor metabolism, larger studies
assessing metabolic fluxes are needed to be able to stratify patients by
driver mutations that confer distinct metabolic vulnerabilities. In this
sense, extensive characterization of metabolic fluxes in multiple cell
lines in culture have proven to be useful to predict sensitivity to pe-
metrexed and dependence on specific metabolic enzymes and nutrients
[42]. Together, these studies will help to clinically define new realistic
therapeutic avenues, specifically for patients harboring non-actionable
mutation profiles or relapsed patients that become resistant to the
current targeted therapies. Metabolic inhibitors could also be helpful in
combination with tyrosine kinases inhibitors which may rewire meta-
bolism. For instance, EGFR inhibitors promote a switch to oxidative
phosphorylation (OXPHOS) that may be exploited to improve their
effects [69]. Along these lines, targeting OXPHOS in combination with
EGFR tyrosine kinase inhibitors (TKI) has been evaluated in a rando-
mized phase 2 clinical trial (NCT03071705) that compared metformin
plus EGFR TKI with EGFR TKI alone in patients harboring EGFR mu-
tations [70]. Patients treated with this combination have significant
benefit in terms of progression-free survival and overall survival com-
pared with those treated with TKI alone [70]. However, another clinical
trial (NCT01864681) did not show benefit when adding metformin to
gefitinib compared to gefitinib alone in non-diabetic NSCLC patients
harboring EGFR mutations [71].
Lastly, diet should be taken into consideration as an extra source of
heterogeneity when studying metabolic parameters in patients, as diet
composition influences strongly the circulating concentrations of glu-
cose and amino acids [51]. We also consider that deeper understanding
of the interplay between tumor and systemic metabolism will be
translated into novel metabolic strategies for therapy, which still need
to be prospectively studied with chemotherapy regimens and even in
combination with immunotherapy or targeted therapy. We foresee a
future in which modulation of systemic metabolism can be incorporated
to the conventional treatment of lung cancer patients, where metabolic
parameters might become as important as genetic mutations in the
treatment of NSCLC.
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